Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO Subscriptions PDA Services My JCO Customer Service

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nam, R. K.
Right arrow Articles by Narod, S. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nam, R. K.
Right arrow Articles by Narod, S. A.
Journal of Clinical Oncology, Vol 21, Issue 12 (June), 2003: 2312-2319
© 2003 American Society for Clinical Oncology

Single Nucleotide Polymorphism of the Human Kallikrein-2 Gene Highly Correlates With Serum Human Kallikrein-2 Levels and in Combination Enhances Prostate Cancer Detection

Robert K. Nam, William W. Zhang, John Trachtenberg, Eleftherios Diamandis, Ants Toi, Marjan Emami, Minnie Ho, Joan Sweet, Andrew Evans, Michael A.S. Jewett, Steven A. Narod

From the Division of Urology, Department of Medical Imaging, Department of Pathology, University Health Network; Department of Pathology and Laboratory Medicine, Mount Sinai Hospital; and the Department of Public Health Sciences, University of Toronto, Toronto, Canada.

Address reprint requests to Robert K. Nam, MD, Division of Urology, 2075 Bayview Ave, MG-406, Toronto, Ontario, Canada, M4N 3M5; email: robert.nam{at}utoronto.ca.

Purpose: We examined the relationship between a mutant (T) for wild-type (C) allele substitution of the human kallikrein-2 gene (KLK2), circulating human kallikrein-2 (hK2) levels and prostate cancer risk.

Patients and Methods: We studied 1,287 consecutive men who underwent prostate biopsies because of an abnormal prostate-specific antigen level. Serum and DNA were obtained before biopsy. Cases were patients with cancer, and controls were patients with no cancer. The mutant and wild-type alleles of the KLK2 gene were designated as the T and C alleles, respectively.

Results: Of the 1,287 men, 616 had cancer, and 671 had no cancer. The overall distribution of the CC, CT, and TT KLK2 genotypes was 55.1%, 38.2%, and 6.8%, respectively. The median hK2 levels for men with the CC, CT, and TT genotypes were 0.24, 0.18, and 0.062 ng/mL and correlated with the genotypes, respectively (P = .0001). The adjusted odds ratios for prostate cancer for patients with the TT and CT genotypes compared with patients with the CC genotype, were 2.13 (95% confidence interval [CI], 1.3 to 3.5; P = .004) and 1.51 (95% CI, 1.2 to 2.0; P = .002), respectively. The adjusted odds ratio for prostate cancer for patients in the fourth quartile of hK2 compared with the first quartile was 4.33 (95% CI, 2.9 to 6.4; P = .0001). When combined, the adjusted odds ratio for having prostate cancer was 13.92 (95% CI, 6.6 to 29.2; P = .0001) for patients with high hK2 levels and at least one T allele.

Conclusion: The C/T polymorphism of the KLK2 gene and circulating levels of hK2 are correlated and, in combination, are highly predictive for prostate cancer.

Supported in part by the National Cancer Institute of Canada (Toronto) and the Canadian Urological Association Young Investigators Award.




This article has been cited by other articles:


Home page
JCOHome page
R. K. Nam, A. Toi, L. H. Klotz, J. Trachtenberg, M. A.S. Jewett, S. Appu, D. A. Loblaw, L. Sugar, S. A. Narod, and M. W. Kattan
Assessing Individual Risk for Prostate Cancer
J. Clin. Oncol., August 20, 2007; 25(24): 3582 - 3588.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
R. K. Nam, W. W. Zhang, L. H. Klotz, J. Trachtenberg, M. A.S. Jewett, J. Sweet, A. Toi, S. Teahan, V. Venkateswaran, L. Sugar, et al.
Variants of the hK2 Protein Gene (KLK2) Are Associated with Serum hK2 Levels and Predict the Presence of Prostate Cancer at Biopsy.
Clin. Cancer Res., November 1, 2006; 12(21): 6452 - 6458.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
R. K. Nam, W. W. Zhang, M. A.S. Jewett, J. Trachtenberg, L. H. Klotz, M. Emami, L. Sugar, J. Sweet, A. Toi, and S. A. Narod
The Use of Genetic Markers to Determine Risk for Prostate Cancer at Prostate Biopsy
Clin. Cancer Res., December 1, 2005; 11(23): 8391 - 8397.
[Abstract] [Full Text] [PDF]


Home page
Mol Cancer ResHome page
C. A. Borgono, I. P. Michael, and E. P. Diamandis
Human Tissue Kallikreins: Physiologic Roles and Applications in Cancer
Mol. Cancer Res., May 1, 2004; 2(5): 257 - 280.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
R. K. Nam, W. W. Zhang, J. Trachtenberg, M. A. S. Jewett, M. Emami, D. Vesprini, W. Chu, M. Ho, J. Sweet, A. Evans, et al.
Comprehensive Assessment of Candidate Genes and Serological Markers for the Detection of Prostate Cancer
Cancer Epidemiol. Biomarkers Prev., December 1, 2003; 12(12): 1429 - 1437.
[Abstract] [Full Text] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 Site Map

Copyright © 2003 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online